Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma

Oral Oncology

Volumn 39, Issue 2, 2003, Pages 163-169

  Yamazaki, Yutaka ^a   Chiba, Itsuo ^b   Hirai, Atsuko ^a   Sugiura, Chihiro ^a   Notani, Ken ichi ^a   Kashiwazaki, Haruhiko ^a   Tei, Kanchu ^a   Totsuka, Yasunori ^a   Fukuda, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Core domain; Mutation; Oral squamous cell carcinoma; P53; Prognosis

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEIN MOTIF; SQUAMOUS CELL CARCINOMA;

AGED; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; SURVIVAL RATE;

EID: 12244262241     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(02)00064-7     Document Type: Article

References (27)

1. Greenblatt M.S., Bennett W.P., Hollstein M., Harris X. Mutations in the p53 tumor suppressor gene. Clues to cancer etiology and molecular pathogenesis Cancer Res. 54(18):1994;4855-4878.
2. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256(5058):1992;827-830.
3. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex. understanding tumorigenic mutations Science. 265(5170):1994;346-355.
4. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol. 14(10):1996;2843-2877.
5. Shimada Y., Imamura M., Shibagaki I., Tanaka H., Miyahara T., Kato M.et al. Genetic Alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg. 226:1997;162-168.
6. Rolley N., Butcher S., Milner J. Specific DNA binding by different classes of human p53 mutants. Oncogene. 11(4):1995;763-770.
7. Pocard M., Chevillard S., Villaudy J., Poupon M.F., Dutrillaux B., Remvikos Y. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to became blocked at the G1/S boundary after irradiation. Oncogene. 12(4):1996;875-882.
8. Bergh J., Norberg T., Sjogren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1(10):1995;1029-1034.
9. Aas T., Borresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E.et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med. 2(7):1996;811-814.
10. Berns E.M.J.J., Van Staveren I.L., Look M.P., Smid M., Klijin J.G.M., Foekens J.A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 77(7):1998;1130-1136.
11. Goh H.S., Yao J., Smith D.R. p53 point mutation and survival in colorectal patients. Cancer Res. 55(15):1995;5217-5221.
12. Borresen A.L., Lothe R.A., Meling G.I., Hainaut P., Rognum T.O., Skovlund E. TP53 and long-term prognosis in colorectal cancer. mutations in the L3 zinc-binding domain predict poor survival Clin Cancer Res. 4(1):1998;203-210.
13. Huang C., Kohno N., Inufusa H., Kodama K., Takai T., Miyake M. Overexpression of bax associated with mutations in the loop-sheet-helix motif of p53. Am J Pathol. 155(3):1999;955-965.
14. Erber R., Conradt C., Homann N., Enders C., Finckh M., Dietz A.et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene. 16(13):1998;1671-1679.
15. Ahomadegbe J.C., Barrois M., Fogel S., Le Bihan M.L., Douc-Rasy S., Duvillard P.et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 10(6):1995;1217-1227.
16. Koch W.M., Brennan J.A., Zahurak M., Goodman S.N., Westra W.H., Schwab D.et al. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst. 88(21):1996;1580-1586.
17. Sobin L.H., Wittekind C. TNM classification of malignant tumors. 5th ed. 1997;International Union Aainst Cancer, Genova, Switzeland.
18. Chiba I., Takahashi T., Nau M.M., D'Amico D., Curiel D.T., Mitsudomi T.et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene. 5(10):1990;1603-1610.
19. Orita M., Suzuki Y., Sekiya T., Hayshi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 5(4):1989;874-879.
20. Chiba I., Shindoh M., Yasuda M., Yamazaki Y., Amemiya A., Sato Y.et al. Mutations in the p53 gene human papillomavirus infection as significant prognostic factors in squamous cell carcinomas of the oral cavity. Oncogene. 12(8):1996;1663-1668.
21. Kashiwazaki H., Tonoki H., Tada M., Chiba I., Shindoh M., Totsuka Y.et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene. 15(22):1997;2667-2674.
22. Ory K., Legros Y., Auguin C., Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13(15):1994;3496-3504.
23. Sigal A., Rotter V. Oncogenic mutations of the p53 tumor suppressor. the demons of the guardian of the genome Cancer Res. 60(24):2000;6788-6793.
24. Ludwig R.L., Bates S., Vousden K.H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol. 16(9):1996;4952-4960.
25. Hiranuma H., Jikko A., Maeda T., Matumura S., Murakami S., Fukuda Y.et al. An analysis of the prognostic significance of p53 status for squamous cell carcinoma of the oral cavity treated by radiotherapy. Oral Oncology. 34(6):1998;513-518.
26. Ostwald C., Gogacz P., Hillmann T., Schweder J., Gundlach K., Kundt G.et al. P53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer. 88(1):2000;82-86.
27. Hussain S.P.V., Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58(15):1998;4023-4037.